CARDIAC PACING LEADS MARKET ANALYSIS

Cardiac Pacing Leads Market, by Product Type (Unipolar, Bipolar, and Others), by Technology (Transcutaneous Pacing, Trans Venous Pacing, and Epicardial Pacing), by End User (Catheterization Labs, Orthopedic Clinics, Hospitals, and Ambulatory Surgery Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

To Be Published : Nov 2024
Code : CMI2675
Formats :
Excel and PDF
Industry : Medical Devices

Market Challenges And Opportunities

Global Cardiac Pacing Leads Market – Drivers and Restraints

The increasing rate of cardiovascular diseases is the primary factor for driving the global cardiac pacing lead market. According to American Heart Association, in 2016, nearly half i.e. 48%, 121.5 million of the adults in the U.S. have cardiovascular diseases. Changing lifestyle of people, increased consumption of fats and sugar, unhealthy work practices and on desk work culture are the factors driving the market globally.

Furthermore, rising number of geriatric population and their chances of cardiac related diseases is the factor driving the market globally. Approvals for the devices associated with the programming of the pacing systems from the regulatory bodies help to drive the market growth. For instance, on May 2, 2019, Medtronic plc received the U.S. FDA approval for careLink SmartSynk device manager, which is used for programming pacing system for cardiac.

The company are developing and launching novel devices to meet the demands of physicians and patients. Moreover, on April 29, 2019, Biotronik launched its Plexa ProMRIs DX lead with DF4/IS-1 connector in Europe. Furthermore, the U.S. Biotronik offers DF4 based DX systems for tachycardia therapy with new lead and recently launched leads Acticor ID and CRT- D devices.

The lack of skilled professionals and less awareness about cardiac disease in public are the factors restraining the market globally.